- A significant advancement has been made in the field of dengue prevention in India. On July 20, 2026, the Drug Controller General of India (DCGI) granted market approval for QDENGA (TAK-003).
- With this, it became India's first approved dengue vaccine.
- The vaccine is approved for individuals aged 4 to 60 years and can play a crucial role in strengthening infection prevention in areas highly affected by dengue.
- QDENGA (TAK-003) is a live-attenuated tetravalent dengue vaccine developed to provide protection against all four major serotypes of the dengue virus.
- A key feature of this vaccine is its suitability for both individuals who have previously contracted dengue and those who have never been infected.
- Consequently, no specific screening or dengue test is required prior to vaccination, making it easier and more effective to conduct large-scale vaccination campaigns.
Tags:
Science
